Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Sep 1, 2010


Qiagen this week launched QIAsymphony RGQ, an automated, fully integrated platform for molecular diagnostic testing and development.

QIASymphony RGQ is modular platform that comprises QIASymphony SP for sample preparation, QIASymphony AS for assay setup, and Rotor-Gene Q real-time PCR thermocycler. Each module can be used individually or combined into a fully integrated system that incorporates all workflow steps from sample to detection, Qiagen said.

The system can process multiple input formats and a varying number of one to 72 samples per run; allows parallel runs and flexible batch sizes; and incorporates intuitive software, Qiagen said.

Qiagen also offers a broad PCR-based assay menu for QIASymphony RGQ, including Artus real-time PCR kits for detecting HIV, hepatitis C virus, hepatitis B virus, and a transplantation panel with cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella-zoster virus, and BK virus. Users can also develop in-house tests on the platform.

Future test offerings for QIASymphony RGQ will include Therascreen EGFR and KRAS tests; and Artus influenza, Chlamydia, Chlamydia/gonorrhea, and an extended transplantation panel. Qiagen also said that future versions of the platform will allow integration of detection options such as pyrosequencing and multiplexing.

QIASymphony RGQ is available for in vitro diagnostic use under the CE Mark. It is not currently available in the US for IVD use.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more